Oppenheimer Asset Management Inc. purchased a new stake in Repligen Corporation (NASDAQ:RGEN) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 2,962 shares of the biotechnology company’s stock, valued at approximately $123,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Ameritas Investment Partners Inc. purchased a new stake in Repligen Corporation in the 1st quarter valued at about $103,000. Victory Capital Management Inc. grew its holdings in Repligen Corporation by 76.6% in the 1st quarter. Victory Capital Management Inc. now owns 3,400 shares of the biotechnology company’s stock valued at $120,000 after buying an additional 1,475 shares during the period. JPMorgan Chase & Co. grew its holdings in Repligen Corporation by 31.9% in the 1st quarter. JPMorgan Chase & Co. now owns 3,755 shares of the biotechnology company’s stock valued at $133,000 after buying an additional 908 shares during the period. US Bancorp DE grew its holdings in Repligen Corporation by 1.2% in the 2nd quarter. US Bancorp DE now owns 4,629 shares of the biotechnology company’s stock valued at $191,000 after buying an additional 54 shares during the period. Finally, Pacad Investment Ltd. grew its holdings in Repligen Corporation by 65.5% in the 2nd quarter. Pacad Investment Ltd. now owns 4,800 shares of the biotechnology company’s stock valued at $199,000 after buying an additional 1,900 shares during the period. Institutional investors own 97.91% of the company’s stock.

Several research firms have commented on RGEN. BidaskClub upgraded Repligen Corporation from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. Zacks Investment Research upgraded Repligen Corporation from a “hold” rating to a “buy” rating and set a $46.00 price target for the company in a report on Saturday, August 12th. TheStreet upgraded Repligen Corporation from a “c+” rating to a “b-” rating in a report on Friday, August 11th. Finally, Jefferies Group LLC restated a “hold” rating and issued a $40.00 price target on shares of Repligen Corporation in a report on Thursday, September 14th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $42.00.

Shares of Repligen Corporation (RGEN) opened at 43.76 on Friday. The firm has a 50-day moving average price of $42.29 and a 200 day moving average price of $39.00. Repligen Corporation has a 12-month low of $26.16 and a 12-month high of $46.81. The stock has a market cap of $1.63 billion, a PE ratio of 85.64 and a beta of 1.21.

Repligen Corporation (NASDAQ:RGEN) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.15 by $0.05. The firm had revenue of $32.40 million during the quarter, compared to the consensus estimate of $31.72 million. Repligen Corporation had a return on equity of 9.90% and a net margin of 15.61%. The business’s revenue for the quarter was up 11.0% on a year-over-year basis. During the same period in the prior year, the business earned $0.16 EPS. Equities research analysts predict that Repligen Corporation will post $0.59 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/09/24/oppenheimer-asset-management-inc-purchases-shares-of-2962-repligen-corporation-rgen.html.

About Repligen Corporation

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN).

Institutional Ownership by Quarter for Repligen Corporation (NASDAQ:RGEN)

Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.